Who Owns Fagron Company?

Who Owns Fagron?

Understanding a company's ownership is key to grasping its strategic path and accountability. Fagron's journey to independence began with its IPO on October 5, 2007, transitioning from an Omega Pharma division to a publicly traded entity.

Founded in 1990, Fagron is a global pharmaceutical compounding company focused on enhancing personalized medication and patient care through its raw materials, equipment, and services for healthcare professionals.

As of July 2025, Fagron has a market capitalization of $1.93 billion USD, with 72.9 million shares outstanding. The company's revenue for the trailing twelve months ending December 31, 2024, was $944 million. Fagron's operations span over 30 countries, employing approximately 3,935 individuals. The company's commitment to innovation is evident in its product offerings, including solutions like the Fagron BCG Matrix, which aids in strategic product portfolio analysis.

Fagron's journey began in 1990, founded by Ger van Jeveren with a focus on distributing raw materials for pharmaceuticals. While initial ownership details are private, the company's early trajectory involved a significant acquisition by Omega Pharma in 2000.

Founder's Vision

Ger van Jeveren established Fagron in 1990. His initial focus was on the distribution of raw materials for medicinal preparations.

Early Acquisition

In 2000, Omega Pharma acquired the original Dutch entity of Fagron from its founder. This marked a significant shift in the company's ownership structure.

Formation of Arseus

By 2006, Arseus was established as an umbrella organization. It integrated Omega Pharma's professional healthcare division, encompassing 35 smaller companies.

Transition to Public Entity

Arseus, which eventually became Fagron NV, went public in 2007. This followed a management buy-out, signaling a move towards broader ownership.

Post-IPO Stake

At the time of the Initial Public Offering (IPO), Omega Pharma held a substantial 24% stake in Arseus. This demonstrates their continued, though diminished, early ownership.

Ownership Evolution

The transition from a private acquisition to a public company via a management buy-out and IPO illustrates a shift from concentrated founder ownership to a more diversified shareholder base.

Understanding the evolution of Fagron's ownership is key to grasping its corporate trajectory and the influences that have shaped its growth. The company's history, including its foundational years and subsequent transformations, provides context for its current standing in the market. For a deeper dive into the company's guiding principles, explore its Mission, Vision & Core Values of Fagron.

Complete Fagron Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Fagron's journey as a public entity began with its IPO on October 5, 2007, marking a significant shift in its ownership landscape. This event paved the way for broader participation from various investor types, influencing its corporate trajectory.

As of July 24, 2025, institutional investors are the dominant force in Fagron's ownership, collectively holding a substantial 74% of the company's shares. This significant stake highlights their considerable influence on Fagron's market performance and strategic decisions. The top four shareholders alone command 50% of the company, demonstrating concentrated ownership among key financial players. Goldman Sachs Group leads this group with 18% of outstanding shares, followed closely by NN Group N.V.'s Asset Management Arm with 16%. Aoc Pharma S.à r.l. holds 11.05%, and Mawer Investment Management Ltd. possesses 5.02%. Further bolstering the institutional backing are FMR LLC with 4.12% and Aberdeen Group with 3.26%. In contrast, individual insiders represent a minor portion of ownership, holding less than 1%, although board members had approximately €2.6 million in shares as of the same date. Fagron's total number of shares with voting rights was 73,313,904 as of July 2, 2025. The company's financial performance in 2024 was robust, with revenue reaching €874.84 million, a 14% increase year-over-year, and net income climbing to €80.55 million.

Key Stakeholders in Fagron's Ownership

Understanding who owns Fagron is crucial for grasping its market dynamics. The company's ownership structure is heavily weighted towards institutional investors, reflecting significant confidence from major financial institutions.

• Institutional investors collectively own 74% of Fagron.
• Goldman Sachs Group is the largest single shareholder at 18%.
• NN Group N.V., Asset Management Arm, holds a significant 16% stake.
• The top four shareholders control 50% of the company's shares.
• Individual insiders hold less than 1% of the company's stock.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

As of May 2, 2025, Fagron's Board of Directors comprises individuals representing significant shareholders alongside independent directors. The current CEO, Rafael Padilla, holds 179,580 shares, and Karin de Jong holds 40,000 shares. The board composition is set to evolve with Ira Bindra joining as a non-executive director, replacing Els Vandecandelaere who will step down on September 30, 2025. Ann Desender BV has been reappointed as an independent non-executive director until the 2029 annual general meeting.

Fagron operates under a strict one-share-one-vote principle, ensuring that each share translates directly into voting power. Shareholders are obligated to report their holdings when they cross key thresholds of 3%, 5%, and subsequent 5% increments. As of July 2, 2025, the total number of voting rights stands at 73,313,904, with no special control mechanisms like golden or founder shares in place. Standard resolutions at general meetings require a simple majority, while significant changes to the articles of association or specific corporate actions necessitate a 75% majority and a quorum representing at least 50% of outstanding shares. The annual general meeting on May 12, 2025, saw the approval of all proposed items, including the 2024 financial statements and a dividend of €0.35 per share for the 2024 fiscal year, reflecting strong support from Fagron shareholders.

Fagron's Corporate Governance and Shareholder Rights

Fagron's corporate structure emphasizes transparency and equitable voting power among its shareholders. The company adheres to a clear voting system and reporting requirements for significant stake acquisitions.

• One-share-one-vote principle ensures equal voting rights.
• Mandatory reporting for shareholding thresholds at 3% and 5%.
• No preferential voting rights or special control structures exist.
• Resolutions typically require a simple majority, with higher thresholds for major changes.
• The Target Market of Fagron is served by a governance structure designed for stability.

Fagron Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Recent strategic maneuvers by Fagron have reshaped its ownership landscape and market standing over the past three to five years. These developments include share repurchases and significant acquisitions aimed at global expansion.

Fagron's proactive approach to mergers and acquisitions has demonstrably broadened its international presence. The company has integrated Guinama in Spain, Uni-Chem and SB Trade in Serbia, and Active Pharma in the UK into its operations. Additionally, the acquisitions of Euro OTC Pharma GmbH and Carefirst Specialty Pharmacy LLC underscore a commitment to a disciplined, value-driven M&A strategy, facilitating entry into new territories such as Australia and Serbia. These strategic moves are designed to bolster Fagron's market position and expand its operational reach. The company's financial health and strategic direction are detailed in its 2024 annual report, published on March 6, 2025. Furthermore, Fagron has announced an annual dividend of €0.2450 per share for the fiscal year 2024, scheduled for payment on May 21, 2025.

Institutional Investor Dominance

Institutional investors hold a significant majority of Fagron's shares, representing 74% as of July 2025. This indicates strong confidence from major financial entities in the company's performance and future prospects.

Concentrated Shareholder Base

The top 25 shareholders collectively own 82.07% of the company as of December 31, 2024. This concentration suggests a stable core group of major Fagron shareholders.

Projected Revenue Growth

Fagron's revenue is projected to grow at an average annual rate of 6.6% over the next three years. This forecast outpaces the 4.9% growth anticipated for the broader European healthcare industry.

Strategic Expansion and M&A Activity

Recent acquisitions, such as Guinama and Active Pharma, highlight Fagron's strategic focus on expanding its global footprint and market share. Understanding these moves is crucial for grasping the Marketing Strategy of Fagron.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE